Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Per the National Alopecia Areata Foundation, about 700,000 people in the United States live with alopecia areata, a disease which has a life-altering impact on patients and limited current treatment options. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
Company Details
- Employees
- 31
- Founded
- -
- Address
- 830 Winter St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.q32bio.com/
- Keywords
- Inflammatory, Research, Clinical Development, Autoimmune, Alopecia Areata, Drug Development.
- HQ
- Waltham, Massachusetts
Q32 Bio Inc. Questions
Q32 Bio Inc.'s website is https://www.q32bio.com/
Q32 Bio Inc.'s LinkedIn profile is https://www.linkedin.com/company/q32-bio-inc
Q32 Bio Inc. has
31 employees.
View email and phone details for 31
employees at Q32 Bio Inc..
Q32 Bio Inc.'s industry is
Biotechnology Research
Q32 Bio Inc.'s top competitors are
Sionna Therapeutics,
Cervomed,
Stoke Therapeutics,
Praxis Precision Medicines, Inc.,
Boundless Bio,
Avalo Therapeutics,
Erasca, Inc.,
Aquestive Therapeutics,
Sunflower Therapeutics,
Avenzo Therapeutics.
Q32 Bio Inc.'s categories are Biotechnology Research
Q32 Bio Inc.'s founding year is 2017
